Notably, BQ-treated BCL-XL KO tumor-bearing mice exhibited significant tumor growth inhibition and minimal treatment-related toxicity (Fig. 6e, f), suggesting that a strategy combining tumor-specific BCL-XL targeting with systemic DHODHi offers a promising therapeutic approach with the potential for reduced toxicity. This evidence concerns the gene BCL2L1 and neoplasm.